Table 2

Timing and dose at treatment discontinuation

Dose of escitalopram

Week of last completed visit

Number of patients discontinued


Due to an AEa

Not due to an AEa


10 mg

Week 0 (baseline)

6

0

Week 8

1

0

20 mg

Week 4

1

0

Week 16

1

0

30 mg

Week 8

1

0

35 mg

Week 8

0

2 (1 - ineligible to continue, 1 - lack of efficacy)

40 mg

Week 24

1

0

45 mg

Week 24

1

1 (lack of efficacy)

50 mg

Week 16

1

0

Week 20

0

1 (lost to follow up)

Week 24

0

1 (lack of efficacy)


a AE: adverse event. The reason for withdrawal was taken from the End of Study Case Report Form (CRF) page. This stated that a patient withdrew due to an AE, although this was not recorded as a withdrawal as a result of an AE on the AE CRF page

Wade et al. BMC Psychiatry 2011 11:42   doi:10.1186/1471-244X-11-42

Open Data